Company recognized as one of Europe’s most innovative businesses in the technology sector
Cambridge, MA - CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has secured an ENTENTE Life Science Investment Forum Award. The award program, which is organized by the ENTENTE project and supported by the European Commission and EuropaBio, recognized CluePoints as one of Belgium’s most innovative high technology businesses for its Central Statistical Monitoring (CSM) solution that employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.
The Belgian edition of the ENTENTE Life Science Investment Forum united 28 European early stage innovative companies, selected from a pool of 100 companies making significant advances in the health sector. The selected companies pitched their innovations and developments to an international judging panel consisting of 50 venture capitalists, corporate investors and industry experts. As a result of being selected for the Belgian ENTENTE award, CluePoints has now qualified to continue along the European Venture contest; a pan-European contest that brings together the top companies from each edition to join the European Venture Summit, taking place 8-9th December 2015 in Dusseldorf, Germany.
“This award win is another real testament to the hard work and unwavering commitment from the CluePoints team”, said Fran?ois Torche, CEO of CluePoints. “We developed our monitoring solutions with a shared belief that we could make a real difference to the way that oversight is approached in clinical trials. We are absolutely delighted to have been recognized by ENTENTE for our efforts”.
For further information on CluePoints’ solutions, please visit www.CluePoints.com
About CluePoints
CluePoints® is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and to drive a risk-based monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.
Help employers find you! Check out all the jobs and post your resume.
